Geovax Labs Inc
GOVX
Company Profile
Business description
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Contact
1900 Lake Park Drive
Suite 380
SmyrnaGA30080
USAT: +1 678 384-7220
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
17
Stocks News & Analysis
stocks
Unconventional wisdom: A controversial income pick
Rigid definitions of income and growth shares may be holding investors back.
stocks
How to avoid dividend disaster
Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks
Why ASX miners will handily beat banks in the long-term
After a stellar run for banks, investors are wondering whether they can continue their outperformance or if a rotation into miners is imminent. There’s a good case that a switch is coming, and it may last decades, not just years.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,780.30 | 4.80 | -0.05% |
| CAC 40 | 8,007.62 | 115.94 | 1.47% |
| DAX 40 | 21,902.42 | 316.49 | 1.47% |
| Dow JONES (US) | 44,747.63 | 125.65 | -0.28% |
| FTSE 100 | 8,727.28 | 103.99 | 1.21% |
| HKSE | 21,083.56 | 191.94 | 0.92% |
| NASDAQ | 19,791.99 | 99.66 | 0.51% |
| Nikkei 225 | 38,787.02 | 279.51 | -0.72% |
| NZX 50 Index | 12,902.19 | 57.60 | 0.45% |
| S&P 500 | 6,083.57 | 22.09 | 0.36% |
| S&P/ASX 200 | 8,511.40 | 9.30 | -0.11% |
| SSE Composite Index | 3,303.67 | 33.01 | 1.01% |